Antibody-mediated LOX-1 inhibition in patients with residual inflammation after myocardial infarction: a randomized phase 2 trial

Journal:
Nature Medicine
Published:
Affiliations:
24
Authors:
28
Institutions Authors Share
Brigham and Women's Hospital (BWH), United States of America (USA)
6.000000
0.21
AstraZeneca Sweden, Sweden
6.000000
0.21
Massachusetts General Hospital (MGH), United States of America (USA)
2.000000
0.07
Cedars-Sinai Medical Center (Cedars-Sinai), United States of America (USA)
1.000000
0.04
Kyoto University Hospital, Japan
1.000000
0.04
Hirakata Kohsai Hospital, Japan
1.000000
0.04
Canisius-Wilhelmina Hospital (CWZ), Netherlands
1.000000
0.04
Flinders University, Australia
1.000000
0.04
Hospital La Paz Institute for Health Research (IdiPAZ), Spain
1.000000
0.04
Medical University of Silesia (SUM), Poland
1.000000
0.04
Johns Hopkins University (JHU), United States of America (USA)
1.000000
0.04
Yale University, United States of America (USA)
0.500000
0.02
VA Connecticut Healthcare System, United States of America (USA)
0.500000
0.02
University of Parma (UNIPR), Italy
0.500000
0.02
Ospedale di Parma, Italy
0.500000
0.02
Charles University (CU), Czech Republic
0.500000
0.02
University Hospital Hradec Králové, Czech Republic
0.500000
0.02
Central Hospital of Northern Pest - Military Hospital, Hungary
0.500000
0.02
Semmelweis University (SE), Hungary
0.500000
0.02
Freeman Hospital, United Kingdom (UK)
0.500000
0.02
Newcastle University, United Kingdom (UK)
0.500000
0.02
D'Or Institute for Research and Education (IDOR), Brazil
0.333333
0.01
Hospital DF Star, Brazil
0.333333
0.01
University of Brasília (UnB), Brazil
0.333333
0.01